$BIIB

aTyr Pharma said it will restructure and cut workforce to fund its planned Phase III efzofitimod program. General counsel Nancy Denyes will step down Sept. 30, 2026, and consult. Biogen named Michael Parini chief legal officer. City Therapeutics appointed Mary Beth DeLena. CytomX named Alejandra Carvajal. Sanofi named Jamie Haney executive VP and general counsel.

Global drugmakers plan major U.S. manufacturing and R&D expansions, citing supply-chain resilience and tariff risk. The article says companies including Pfizer, GSK, Eli Lilly, J&J, Roche, AstraZeneca, Novartis, Sanofi, Biogen, Merck, Amgen, AbbVie, Gilead, Bristol Myers Squibb, Cipla, and CSL have pledged about US$500 billion. Examples include Pfizer’s US$70B, Lilly’s US$27B-plus, and Merck’s US$70B-plus.

Biogen and Ionis’ tofersen (Qalsody) for SOD1-ALS is linked to stabilization or improvement in some patients, including a reported case of reversal after dose escalation. Qalsody was FDA approved in April 2023 based on biomarker data and is marketed in the US and Canada. AL-S Pharma’s AP-101 is also in trials.

Biogen Inc. (Nasdaq: BIIB) said it has completed its acquisition of RayThera Inc., a privately held immunology-focused biotech. Biogen said the deal adds multiple small-molecule assets to its immunology pipeline, with a lead program that entered Phase 1 development in July 2026. The company did not provide deal terms.

Biogen (Nasdaq: BIIB) said it has completed its acquisition of privately held RayThera Inc., which focuses on small-molecule immunology therapies. Biogen stated the deal adds multiple assets for immune-mediated conditions, and RayThera’s lead program entered Phase 1 development in July 2026. The release provides no deal economics.

Biogen (BIIB) said it is extending an open-label long-term extension study of felzartamab in kidney transplant patients with prior antibody-mediated rejection or microvascular inflammation. The trial follows participants for up to about four years to assess long-run safety and outcomes, with felzartamab infusions every eight weeks for some patients. No primary completion dates were provided.

The article highlights biotech stocks Incyte (INCY) and Biogen (BIIB) on Josh Brown’s “Best Stocks” list, saying both are near summer highs. It cites INCY Q2 revenue of $1.67B and adjusted EPS $3.09, plus raised net sales guidance to $5.13B-$5.26B. For BIIB, it cites Q2 revenue $2.74B and adjusted EPS $3.60, plus FDA approval and Apellis acquisition.

Biogen (BIIB) reported upbeat Q2 updates, citing faster uptake of high-dose SPINRAZA, a new subcutaneous home-dosing option for LEQEMBI IQLIK, and double-digit revenue gains from integrating Apellis assets SYFOVRE and Empaveli. Management expects five Phase 3 readouts in four quarters and $250 million run-rate synergies by 2027, while warning of near-term margin pressure. BIIB shares trade around $207.

Business of San Diego cites Carta data saying San Diego ranks 7th nationally for venture capital financings this year. It lists AI startups emerging from stealth, and notes four local firms that went public in 2026, including Solv Energy, Aevex Aerospace, Atrium, and Suja Juice, raising over $1.5B. It also covers deals such as Crinetics Pharmaceuticals to be acquired by Vertex for $10B and Qualcomm buying Modular for $3.9B.

Simply Wall St reports Biogen (BIIB) shares were slightly down Friday and flat over the week ahead of its earnings. Q2 revenue was $2.7b, steady year over year, but basic EPS fell to $0.66 from $2.17 in Q1. Trailing net margin dropped to 8.3% from 15.3% as net income declined to $97.5m. The article cites Apellis-related growth and one-off charges.